Kurt von Emster

Kurt von Emster is a distinguished Managing Partner at Abingworth, a renowned life science investment firm located in London, Menlo Park CA, and Boston. Abingworth specializes in therapeutic investment opportunities across the spectrum from preclinical to commercial stages. Kurt is actively involved in managing the firm's 12th venture fund, known as Abingworth Bioventures 7. Despite being based in California, he plays a crucial role in the global sourcing and execution of deals.

Kurt von Emster pursued his Bachelor of Science (BS) degree in Business and Economics at the University of California, Santa Barbara, laying a solid foundation for his successful career in the field of life science investments.

Throughout his career, Kurt von Emster has held key positions in various prominent organizations. He currently serves as the Managing Partner at Abingworth. Additionally, he has an extensive history of serving on the boards of several notable companies including Tizona Therapeutics, Vera Therapeutics, Trishula Therapeutics, ORBUS THERAPEUTICS, SFJ Pharmaceuticals, Jasper Therapeutics, SutroVax Inc., CymaBay, Kesios Therapeutics, CRISPR Therapeutics, Aurinia Pharmaceuticals, Cytos Biotechnology, venBio LLC, Facet Biotech, Somaxon Pharmaceuticals, and MPM Capital.

Kurt von Emster's experience also includes his role as the Founding Partner at venBio LLC, as well as serving as the Vice President of Portfolio Management at Franklin Templeton Investments. His diverse background showcases his expertise and leadership in the life science investment arena.